Dexloxiglumide

Drug Profile

Dexloxiglumide

Alternative Names: CR-2017

Latest Information Update: 11 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rottapharm
  • Developer Forest Laboratories; Rottapharm Madaus
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Pentanoic acids; Small molecules
  • Mechanism of Action Cholecystokinin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastro-oesophageal reflux; Irritable bowel syndrome; Non-ulcer dyspepsia
  • Discontinued Sleep apnoea syndrome

Most Recent Events

  • 15 Oct 2015 Discontinued - Phase-II for Sleep apnoea syndrome (Treatment-naive) in Italy (PO)
  • 04 Aug 2015 Phase III development for Irritable bowel syndrome, Gastro-oesophageal reflux and Non-ulcer dyspepsia is ongoing in Europe
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top